Skip to main content
Caplight Logo









Lucence

Lucence

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.lucence.com/

Last Round

Series A

Extension

Nov 10, 2023

Total Funding Raised

$74.35M

Company Overview

Lucence is a precision oncology company that develops non-invasive liquid biopsy tests for early cancer detection and treatment selection.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

liquid biopsyprecision oncologycancer blood testcancer detectiongenomic testingmolecular diagnosticstargeted therapy selectionmulti-cancer early detectionMCEDearly cancer detectionAI cancer detectionctDNA analysisctRNA analysistreatment response monitoringhereditary cancer risktissue-of-origin predictionCLIA licensed labCAP accredited lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lucence Comparables

Compare Lucence with similar companies based on industry and business-model similarity.

Lucence comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Predicine
83%
Circulogene
83%
Guardant Health
80%

Lucence Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionNov 10, 2023
Series ANov 20, 2019

Key People

Founding team and executive leadership

Edwin C.

Advisor To CEO

Executive Team

Michelle Pek

CTO

Executive Team

Lucence Investors

Notable investors and investment history

Lucence investors
InvestorRounds
Chen Capital VenturesSeries A Extension
Heliconia CapitalSeries A, Series A Extension
SGInnovateSeries A
Openspace CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 15, 2025

    Grew 18% QoQ, from 83 to 98 employees.

  • Jul 1, 2025

    Monthly visitors increased 88% MoM, reaching 3,000.

Lucence Filings

Explore SEC and related filing metadata, where available.

Lucence filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lucence's valuation, stock price, and market status.

Is Lucence a public or private company?

Lucence is a private company.

What is the current stock price of Lucence?

Lucence is a private company with no public stock price. No recent secondary market data is available.

How much is Lucence worth (valuation)?

Valuation information for Lucence is not publicly available.

Can I buy Lucence stock?

Lucence shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lucence's last funding round?

Lucence's most recent funding round was Series A Extension on November 10, 2023.

Who are the main investors in Lucence?

Key investors in Lucence include Chen Capital Ventures, Heliconia Capital, Openspace Capital.

Will Lucence IPO soon?

No public IPO plans have been announced for Lucence.

How can I track Lucence secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lucence's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range76
Year Founded2016
Last FundingNov 10, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?